0001209191-22-014438.txt : 20220301
0001209191-22-014438.hdr.sgml : 20220301
20220301211034
ACCESSION NUMBER: 0001209191-22-014438
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220225
FILED AS OF DATE: 20220301
DATE AS OF CHANGE: 20220301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chevallard Daniel R.
CENTRAL INDEX KEY: 0001706176
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51531
FILM NUMBER: 22700942
MAIL ADDRESS:
STREET 1: C/O REGULUS THERAPEUTICS INC.
STREET 2: 10614 SCIENCE CENTER DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viracta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001061027
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943295878
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
BUSINESS PHONE: 858-400-8470
MAIL ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
FORMER COMPANY:
FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980709
FORMER COMPANY:
FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-25
0
0001061027
Viracta Therapeutics, Inc.
VIRX
0001706176
Chevallard Daniel R.
C/O VIRACTA THERAPEUTICS, INC.
2533 S COAST HWY 101, SUITE 210
CARDIFF
CA
92007
0
1
0
0
CFO and COO
Common Stock
2022-02-25
4
M
0
6889
0.00
A
79847
D
Common Stock
2022-02-28
4
S
0
3998
2.7795
D
75849
D
Restricted Stock Units
2022-02-25
4
M
0
6889
0.00
D
Common Stock
6889
89555
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
Represents the weighted average share price of an aggregate total of 3,998 shares sold in the price range of $2.7101 to $2.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.
/s/ Shelly Vandertie, as Attorney-in-Fact
2022-03-01